The biomarker paradigm: Between diagnostic efficiency and clinical efficacy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 4, 2015, Pages 282-288

  Lippi, Giuseppe ^a   Mattiuzzi, Camilla ^b  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b Trento General Hospital   (Italy)

Author keywords

Accuracy; Biomarkers; Effectiveness; Efficacy; Efficiency

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; MANAGED CARE; CLINICAL DECISION MAKING; TREATMENT OUTCOME;

BIOMARKERS; CLINICAL DECISION-MAKING; HUMANS; TREATMENT OUTCOME;

EID: 84929237081     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2788     Document Type: Article

References (31)

1. Hallworth MJ. The '70% claim': what is the evidence base? Ann Clin Biochem. 2011; 48: 487-488.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95.
3. Encyclopedia Britannica. http://www.merriam-webster.com/. Accessed November 26, 2014.
4. Bennett BM. On generalized indices of diagnostic efficiency. Biom J. 1982; 24: 59-62.
5. Lippi G, Mattiuzzi C, Cervellin G. Biomarker validation in the emergency department. General criteria and clinical implications. Emerg Care J. 2014; 10: 1806.
6. Eusebi P. Diagnostic accuracy measures. Cerebrovasc Dis. 2013; 36: 267-272.
7. Shein-Chung C, LiuJP. Design and analysis of clinical trials: concepts and methodologies. Vol. 979. John Wiley & Sons, 2013.
8. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010; 341: c4543.
9. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013; 1: CD004 720.
10. Lippi G, Montagnana M, Guidi GC, Plebani M. Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype? Ann Med. 2009; 41: 480-489.
11. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014; 6: 74-77.
12. Gates TJ. Screening for cancer: concepts and controversies. Am Fam Physician. 2014; 90: 625-631.
13. Patel KV, Semba RD, Ferrucci L, et al. Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2010; 65: 258-265.
14. Lippi G, Plebani M. Red blood cell distribution width (RDW) and human pathology. One size fits all. Clin Chem Lab Med. 2014; 52: 1247-1249.
15. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009; 361: 858-867.
16. Li WJ, Chen XM, Nie XY, et al. The early diagnostic and prognostic utility of high-sensitive troponin assays in acute myocardial infarction: a meta-analysis. Intern Med J. 2014 Nov 18. doi: 10.1111/imj.12 642. [Epub ahead of print].
17. Chatterjee S, Kim J, Dahhan A, et al. Use of high-sensitivity troponin assays predicts mortality in patients with normal conventional troponin assays on admission-insights from a meta-analysis. Clin Cardiol. 2013; 36: 649-653.
18. Ahmed AN, Blonde K, Hackam D, et al. Prognostic significance of elevated troponin in non-cardiac hospitalized patients: A systematic review and meta-analysis. Ann Med. 2014; 46: 653-663.
19. Lippi G, Plebani M. Biomarker research and leading causes of death worldwide: a rather feeble relationship. Clin Chem Lab Med. 2013; 51: 1691-1693.
20. Lippi G, Plebani M, Guidi GC. The paradox in translational medicine. Clin Chem. 2007; 53: 1553.
21. Guest PC, Gottschalk MG, Bahn S. Proteomics: improving biomarker translation to modern medicine? Genome Med. 2013; 5: 17.
22. Grant RP, Hoofnagle AN. From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. Clin Chem. 2014; 60: 941-944.
23. Steen RG. Retractions in the scientific literature: is the incidence of research fraud increasing? J Med Ethics. 2011; 37: 249-253.
24. Simundic AM, Kackov S, Miler M, et al. Terms and Symbols Used in Studies on Biological Variation: The Need for Harmonization. Clin Chem. 2015; 61: 438-439.
25. Lippi G, Cervellin G. Choosing troponin immunoassays in a world of limited resources. J Am Coll Cardiol. 2013; 62: 647-648.
26. Hilborne L. Choosing wisely: selecting the right test for the right patient at the right time. MLO Med Lab Obs. 2014; 46: 40.
27. Lippi G, Plebani M. False myths and legends in laboratory diagnostics. Clin Chem Lab Med. 2013; 51: 2087-2097.
28. Favaloro EJ, Plebani M, Lippi G. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing? Clin Chem Lab Med. 2011; 49: 1965-1973.
29. Dasgupta A, Nair P. When are biomarkers useful in the management of airway diseases? Pol Arch Med Wewn. 2013; 123: 183-188.
30. Haynes SN, Lench HC. Incremental validity of new clinical assessment measures. Psychol Assess. 2003; 15: 456-466.
31. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011; 123: 551-565.